苹果酸舒尼替尼治疗多次复发的晚期非小细胞肺癌疗效与安全性分析  

Efficacy and Safety of Albumin-bound Paclitaxel in Treating Recurrent Advanced Non-small Cell Lung Cancer

作　　者：邢镨元[1] 李峻岭[1] 石远凯[1] 

机构地区：[1]北京协和医学院,中国医学科学院肿瘤医院内科,抗肿瘤分子靶向药物临床研究北京市重点实验室,北京100021

出　　处：《中国肺癌杂志》2013年第10期519-523,共5页Chinese Journal of Lung Cancer

基　　金：国家"重大新药创制"科技重大专项"十一五"课题(No.2008ZX09312-020);国家"重大新药创制"科技重大专项"十二五"课题(No.2012ZX09303-012);北京市科技计划项目(No.Z111102071011001);中央保健课题(No.B2009B124)资助~~

摘　　要：背景与目的晚期非小细胞肺癌是一种无法治愈的常见恶性肿瘤。对于多程治疗后复发的患者目前尚无标准的治疗方法。本文分析了苹果酸舒尼替尼单药治疗多次复发的晚期非小细胞肺癌的疗效及安全性。方法回顾性分析我科2011年1月-2012年12月采用苹果酸舒尼替尼37.5 mg/d持续给药的方法治疗的17例多程治疗后复发的晚期非小细胞肺癌患者的近期疗效、毒副反应及无进展生存时间。结果 17例患者中部分缓解1例(5.9%),稳定7例(41.2%),疾病进展9例(52.9%),客观缓解率5.9%,疾病控制率47.1%,中位无进展生存为4.4个月(95%CI:4.05-7.46)。全组患者治疗耐受良好,3级/4级不良反应仅表现为手足皮肤反应(5.9%),其余药物相关不良事件均为1/2级。结论苹果酸舒尼替尼37.5 mg/d持续治疗多程治疗后复发的晚期非小细胞肺癌可取得较好的客观疗效,耐受良好。Background and objective Advanced non-small cell lung cancer （NSCLC） is a common malignancy that is incurable. No standard treatment exists for recurrent patients. hTis article analyzed the effcacy and safety of sunitinib （37.5 mg qd） on a continuous daily dosing （CDD） schedule in treating recurrent advanced NSCLC. Methods We retrospec-tively analyzed the short-term effcacy and toxicity of sunitinib CDD in treating 17 patients who had previously undergone multiple cycles of therapy for advanced NSCLC in our hospital from January 2011 to December 2012. Treatment-related survival was also analyzed. Results Among the 17 patients, the best overall response was partial response in 1 patient （5.9%）, stable disease in 7 patients （41.2%）, and progressive disease in 9 patients （52.9%）. hTe overall response rate was 5.9%, and the disease control rate was 47.1%. hTe median progression-free survival was 4.4 months （95%CI：4.05-7.46）. hTe main grade 3/4 toxicity was hand-foot skin reaction. Conclusion Sunitinib （37.5 mg QD） CDD enabled good objective response in advanced NSCLC patients who had previously received multiple cycles of treatment and was well tolerated.

关 键 词：肺肿瘤 苹果酸舒尼替尼 复发 酪氨酸激酶抑制剂 

分 类 号：R734.2[医药卫生—肿瘤]